Lataa...
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
BACKGROUND: The compound letermovir (LMV) has recently been approved for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant. LMV inhibits CMV replication by binding to the viral terminase complex. Ho...
Tallennettuna:
| Julkaisussa: | BMC Infect Dis |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6505103/ https://ncbi.nlm.nih.gov/pubmed/31068147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-019-4016-1 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|